NM
BOLT icon

Newtyn Management’s Bolt Biotherapeutics BOLT Stock Holding History

Newtyn Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,446
Closed -$304K – 35
2024
Q3 		$304K Sell
23,446
-44,716
-66% -$616K 0.05% 39
2024
Q2 		$1.02M Sell
68,162
-16,838
-20% -$332K 0.19% 35
2024
Q1 		$2.38M Buy
85,000
+7,323
+9% +$170K 0.47% 29
2023
Q4 		$1.74M Buy
77,677
+26,677
+52% +$519K 0.34% 33
2023
Q3 		$1.06M Buy
51,000
+1,000
+2% +$24.4K 0.26% 38
2023
Q2 		$1.28M Sell
50,000
-5,756
-10% -$183K 0.3% 35
2023
Q1 		$1.55M Sell
55,756
-1,744
-3% -$51K 0.3% 52
2022
Q4 		$1.5M Buy
57,500
+27,500
+92% +$754K 0.31% 42
2022
Q3 		$888K Sell
30,000
-7,413
-20% -$307K 0.2% 58
2022
Q2 		$1.53M Buy
+37,413
New +$1.45M 0.29% 50

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Newtyn Management's BOLT Position: Q4 2024 in Review

Newtyn Management sold out of Bolt Biotherapeutics (BOLT) in Q4 2024, closing a stake of 23,446 shares — an estimated $304K sold.

Newtyn Management first reported a position in BOLT in Q2 2022 and held it in 10 quarters. The position peaked at $2.38M in Q1 2024. 37 funds tracked by Wall St. Rank hold BOLT as of Q4 2024.

  • Newtyn Management reported no remaining Bolt Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Newtyn Management sold 23,446 Bolt Biotherapeutics shares in Q4 2024, an estimated $304K.
  • Newtyn Management first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 10 quarters.
  • Newtyn Management's Bolt Biotherapeutics position peaked at $2.38M in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2024.

Based on Newtyn Management's 13F filing for Q4 2024, filed 14 Feb 2025.